Description of Invention:
Molecules based on monoclonal antibodies hold the promise of highly selective therapeutics. However, their efficacy can be limited by poor tissue penetration, rapid renal clearance and an immune response to the antibody. The present technology provides an immunotoxin that is modified to overcome such limitations.
The technology relates to polymer-conjugated immunotoxins targeted to the mesothelin tumor cell antigen. These polymer-immunotoxin conjugates possess an enhanced therapeutic index and may provide improved methods of treating tumors and cancers expressing the mesothelin antigen.
Inventors:
Ira Pastan (NCI) et al.
Patent Status:
DHHS Reference No. E-121-2005/0 --
U.S. Provisional Application No. 60/636,007 filed 12 Dec 2004
PCT Application No. PCT/US2005/045177 filed 14 Dec 2005
Portfolios: Cancer
Cancer -Therapeutics-Immunoconjugates-Toxins Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
